Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003773527 | SCV004590961 | pathogenic | Episodic ataxia type 2; Developmental and epileptic encephalopathy, 42 | 2023-02-28 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Asn2062Leufs*60) in the CACNA1A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CACNA1A are known to be pathogenic (PMID: 10371528, 19486177, 25735478, 27250579). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with CACNA1A-related conditions. ClinVar contains an entry for this variant (Variation ID: 1526277). For these reasons, this variant has been classified as Pathogenic. |
Génétique des Maladies du Développement, |
RCV002052295 | SCV002318932 | pathogenic | Developmental and epileptic encephalopathy, 42 | no assertion criteria provided | clinical testing | ||
Prevention |
RCV004729060 | SCV005335892 | pathogenic | CACNA1A-related disorder | 2024-09-27 | no assertion criteria provided | clinical testing | The CACNA1A c.6181_6184delAACT variant is predicted to result in a frameshift and premature protein termination (p.Asn2061Leufs*60). To our knowledge, this variant has not been reported in the literature or in a large population database, indicating this variant is rare. Loss of function variants in CACNA1A have been shown to be pathogenic (Damaj et al. 2015. PubMed ID: 25735478; Denier et al. 1999. PubMed ID: 10371528). This variant is interpreted as pathogenic. |